World News: 00:17 GMT Friday 11th January 2019. [Bragar Eagel & Squire via Globe Newswire via SPi World News]
NEW YORK, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Aphria Inc., NVIDIA Corporation, DXC Technology Company, and Immunomedics, Inc. Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Class Period: July 17, 2018 - December 4, 2018
Lead Plaintiff Deadline: February 4, 2019
The complaint alleges that throughout the class period defendants made materially false and misleading statements and failed to disclose to investors: (i) that Latin American assets acquired by the company lacked adequate licenses to operate and were overvalued; and (ii) that the acquisition of Latin American assets would enrich the company’s CEO and other insiders at the expense of shareholders. The complaint further alleges that, as a result of the foregoing, investors purchased Aphria’s securities at artificially inflated prices during the Class Period and suffered investment losses as a result of defendants’ conduct.
To learn more about the Aphria class action go to: .
Class Period: August 10, 2017 - November 15, 2018
Lead Plaintiff Deadline: February 19, 2019
The complaint alleges that throughout the class period defendants assured investors that the company followed the market closely and could adjust to rapid changes in the cryptocurrency markets. Even as analysts increasingly began to question the company’s ability to manage inventory in the face of an uncertain cryptocurrency market, defendants touted that NVIDIA and its executives are “masters at managing our channel, and we understand the channel very well.” NVIDIA also repeatedly assured investors that surging demand for Graphics Processing Units (“GPUs”) among cryptocurrency miners would not have a negative impact on the company because of strong demand for GPUs by NVIDIA’s core customer base of computer gamers.
To learn more about the NVIDIA class action go to: .
Class Period: February 8, 2018 - November 6, 2018
Lead Plaintiff Deadline: February 25, 2019
The complaint alleges that throughout the class period defendants made false and misleading statements and/or failed to disclose adverse information regarding the company’s business and prospects. Specifically, defendants failed to disclose that the company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; that the company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; and that, as a consequence, the company’s revenue and financial performance guidance for fiscal 2019 was without a reasonable basis.
To learn more about the DXC class action go to: .
Class Period: August 23, 2018 - December 20, 2018
Lead Plaintiff Deadline: February 25, 2019
The complaint alleges that throughout the class period defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. On December 17, 2018, FDAnews.com published an article titled “FDA Hits Immunomedics for Data Integrity Breach.” According to this article, “[t]he FDA cited Immunomedics for a host of violations - including its handling of a data integrity breach - observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.” The article states that this breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”
To learn more about the Immunomedics class action go to: .
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to . Attorney advertising. Prior results do not guarantee similar outcomes.
ContactsBragar Eagel & Squire, P.C.Brandon Walker, Esq.Melissa Fortunato, Esq.(212) 355-4648
Globe Newswire: 00:17 GMT Friday 11th January 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.